Atlantic Union Bankshares Corp Has $7.86 Million Stock Position in Eli Lilly and Company (NYSE:LLY)

Atlantic Union Bankshares Corp lowered its position in shares of Eli Lilly and Company (NYSE:LLY) by 4.8% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 10,109 shares of the company’s stock after selling 508 shares during the quarter. Atlantic Union Bankshares Corp’s holdings in Eli Lilly and Company were worth $7,864,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Trexquant Investment LP bought a new stake in shares of Eli Lilly and Company during the 3rd quarter worth approximately $3,874,000. Morningstar Investment Services LLC raised its stake in shares of Eli Lilly and Company by 112.8% during the 3rd quarter. Morningstar Investment Services LLC now owns 1,741 shares of the company’s stock worth $948,000 after purchasing an additional 923 shares in the last quarter. Cape Cod Five Cents Savings Bank raised its stake in Eli Lilly and Company by 101.6% in the 3rd quarter. Cape Cod Five Cents Savings Bank now owns 5,126 shares of the company’s stock valued at $2,753,000 after acquiring an additional 2,583 shares during the period. CWA Asset Management Group LLC raised its stake in Eli Lilly and Company by 13.9% in the 3rd quarter. CWA Asset Management Group LLC now owns 2,465 shares of the company’s stock valued at $1,324,000 after acquiring an additional 300 shares during the period. Finally, Teza Capital Management LLC acquired a new position in Eli Lilly and Company in the 3rd quarter valued at $4,313,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Bank of America reaffirmed a “buy” rating and issued a $1,000.00 price objective on shares of Eli Lilly and Company in a report on Monday, June 24th. Citigroup increased their target price on Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a report on Tuesday, April 2nd. JPMorgan Chase & Co. raised their price objective on Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a research note on Wednesday, May 1st. Jefferies Financial Group raised their price objective on Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a research note on Monday, June 24th. Finally, Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $812.72.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 750 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $819.47, for a total value of $614,602.50. Following the completion of the sale, the chief accounting officer now owns 7,130 shares of the company’s stock, valued at $5,842,821.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CAO Donald A. Zakrowski sold 750 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $819.47, for a total transaction of $614,602.50. Following the transaction, the chief accounting officer now owns 7,130 shares of the company’s stock, valued at $5,842,821.10. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Lilly Endowment Inc sold 9,671 shares of Eli Lilly and Company stock in a transaction that occurred on Thursday, June 20th. The shares were sold at an average price of $902.67, for a total value of $8,729,721.57. Following the transaction, the insider now directly owns 97,574,139 shares in the company, valued at approximately $88,077,248,051.13. The disclosure for this sale can be found here. Over the last quarter, insiders sold 789,704 shares of company stock valued at $672,385,964. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Trading Down 0.3 %

Shares of Eli Lilly and Company stock opened at $905.87 on Friday. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35. Eli Lilly and Company has a 52 week low of $434.34 and a 52 week high of $915.54. The stock has a 50 day moving average price of $814.40 and a two-hundred day moving average price of $738.79. The stock has a market capitalization of $860.95 billion, a PE ratio of 133.41, a price-to-earnings-growth ratio of 1.98 and a beta of 0.36.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Monday, May 6th. The company reported $2.58 EPS for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The firm had revenue of $8.77 billion during the quarter, compared to analysts’ expectations of $8.94 billion. During the same quarter last year, the firm posted $1.62 earnings per share. The company’s revenue for the quarter was up 26.0% compared to the same quarter last year. As a group, equities analysts anticipate that Eli Lilly and Company will post 13.76 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.57%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 76.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.